Speaker Profile
M.D., Senior Vice President, Clinical Development, Clasp Tx
Biography
Dr. Harshman leads the Clinical Development efforts at Clasp Therapeutics. A medical oncologist, she brings over 15 years of experience as a practicing physician and clinical trialist first at the patient bedside and now in biotech leadership. Most recently, Lauren served as Vice President of Clinical Development at Surface Oncology, before its acquisition by Coherus Biosciences. Earlier in her career, Dr. Harshman was on faculty at Harvard Medical School and Dana-Farber Cancer Institute, where she served as Co-Director of the Kidney Cancer Center and as a Senior Physician in the Division of Oncology. She is a graduate of Cornell University and Chicago Medical School, completed her internal medicine residency at Yale, and her medical oncology fellowship at Stanford, where she later joined the faculty at Stanford Cancer Institute and Stanford School of Medicine.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 Emerging Therapeutics Showcase will provide a 15-30 minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.
- Emerging Therapeutics/Cell Therapy
- Emerging Therapeutics/CVD
- Emerging Therapeutics/Gene Therapy
- Emerging Therapeutics/Immunotherapy
- Emerging Therapeutics/Radiation Therapy
